Preclinical and first-in-human pilot evaluation of 177Lu-DOTA-7ND for fibroblast activation protein-α-targeted radionuclide imaging and therapy.
Fibroblast activation protein-α (FAP) is an attractive cell surface target for radiopharmaceutical development due to its tumor-restricted expression. This study aimed to develop a novel dimeric FAP inhibitor (FAPI), DOTA-PEG4-CO-N-bis(PEG4-7N) (D7ND), and evaluate its potential as a therapeutic radiopharmaceutical in...